ZBD(SH:603567)2016-05-06 16:00Financial Performance - The company achieved a net profit attributable to shareholders of 585,305,007.62 RMB in 2015, representing a 22.63% increase from 477,300,085.31 RMB in 2014[4]. - Total revenue for 2015 was 2,073,059,862.24 RMB, a 30.14% increase compared to 1,592,911,248.62 RMB in 2014[21]. - The net assets attributable to shareholders at the end of 2015 were 4,002,989,167.84 RMB, an increase of 82.91% from 2,188,498,343.14 RMB at the end of 2014[21]. - The total assets of the company reached 5,949,674,930.57 RMB at the end of 2015, up 65.08% from 3,604,080,674.97 RMB in 2014[21]. - Basic earnings per share increased by 9.53% to CNY 1.4522 compared to the previous year[22]. - Quarterly revenue for Q4 reached CNY 805,464,213.31, with a net profit attributable to shareholders of CNY 290,824,918.77[23]. - The pharmaceutical industrial revenue was 1.978 billion RMB, with a gross margin of 81.25%, up 18.18 percentage points year-on-year[49]. - The company achieved a revenue of 2.073 billion RMB, representing a year-on-year growth of 30.14%[45]. - The company reported a significant increase in deferred income, which rose by 145.55% due to government subsidies received during the reporting period[67]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of 5.00 RMB per 10 shares, totaling an expected cash dividend payout of 212,290,000.00 RMB[4]. - The cash dividend represents 36.27% of the net profit attributable to shareholders for the year 2015[133]. - The company has revised its profit distribution policy to emphasize sustainable returns to investors while ensuring the company's long-term development[130]. - The profit distribution proposal has been approved by the company's board and is pending approval from the shareholders' meeting[131]. - The company has maintained a stable profit distribution policy over the past three years, with cash dividends in previous years being RMB 200,000,000.00 in 2014 and RMB 40,000,000.00 in 2013[133]. Research and Development - The company holds 102 patents, including 50 invention patents, and has established a strong R&D capability with 620 technical R&D personnel, accounting for 18% of the total workforce[35]. - The R&D expenditure increased by 37.42% to 93 million RMB, reflecting the company's commitment to innovation[47]. - The company has 12 products under development, focusing on areas such as antibiotics, oncology, cardiovascular diseases, diabetes, and digestive system treatments[62]. - The company plans to enhance its R&D efforts in chemical raw materials and formulations, particularly in oncology and cardiovascular drugs, as well as traditional and modern Chinese medicine[77]. - The company aims to enhance its product portfolio by increasing R&D efforts and adapting to market changes[85]. Market and Industry Trends - The pharmaceutical industry output value reached CNY 175.88 billion in the first eight months of 2015, with a growth rate of 11.7%, and the total industrial output value for the year is expected to reach CNY 288.42 billion, growing by 11.8%[31]. - The terminal market size for pharmaceuticals in China was CNY 1,036.6 billion in the first nine months of 2015, with an expected annual growth rate of 11%, down 11.9 percentage points from the "Eleventh Five-Year Plan" period[31]. - The overall pharmaceutical industry output value is expected to reach 288.42 billion RMB in 2015, growing at 11.8%[42]. - The healthcare market in China is projected to reach nearly 4 trillion, driven by an aging population and increasing demand for medical services, prompting the company to invest in related healthcare projects[123]. Operational Efficiency - The company reduced its operating costs by 22.79%, amounting to 454 million RMB, primarily due to a decrease in the price of key raw materials[47][51]. - The company has established a quality management department with multiple laboratories and has implemented strict quality control standards exceeding national drug standards[36]. - The company has implemented a comprehensive quality management system for traditional Chinese medicine materials to ensure product quality[43]. - The company aims to enhance production efficiency and promote green development through the integration of new technologies and industrial upgrades[118]. Risk Management - The company has not identified any significant risks that could materially affect its operations during the reporting period[6]. - The company faces risks from policy changes, market competition, and product counterfeiting, necessitating adaptive strategies to mitigate these risks[125][126]. - The company is committed to improving its risk management capabilities and enhancing overall competitiveness in response to various market challenges[127]. Corporate Governance - The company has established a comprehensive corporate governance structure that complies with the Company Law and the relevant regulations of the China Securities Regulatory Commission[192]. - The company has set up four specialized committees within the board: audit, strategy, nomination, and remuneration and assessment, operating in compliance with relevant laws and regulations[190]. - The company ensures fair treatment of all shareholders, particularly minority shareholders, in accordance with legal requirements[190]. Shareholder Structure - The largest shareholder, Hulin Chuangda Investment Co., Ltd., holds 288,000,000 shares, representing 67.83% of the total shares, with all shares pledged[159]. - The second largest shareholder, Hulin Longpeng Investment Center (Limited Partnership), holds 72,000,000 shares, accounting for 16.96% of the total shares[159]. - The top ten shareholders include various funds and trusts, with the smallest holding being 330,000 shares, which represents 0.08% of the total shares[160]. - The company has no strategic investors or general legal entities that have become top ten shareholders through new share placements[163]. Employee and Management - The total number of employees in the parent company is 636, while the total number of employees in major subsidiaries is 2,808, resulting in a combined total of 3,444 employees[184]. - The company has established a talent training system to enhance management capabilities and promote team cohesion[145]. - The total remuneration for all directors, supervisors, and senior management during the reporting period amounted to 4.2131 million yuan[182]. Social Responsibility - The company has actively engaged in social responsibility initiatives, including charitable donations and community support activities[146]. - Environmental protection measures have been enhanced, including the expansion of wastewater treatment facilities and improvements in emissions control[147].